NSP · Insperity, Inc

The thesis

Insperity's margin-repair recovery is still unproven, and the third-quarter report released before the NYSE open on 29 October 2026 settles whether the $185 million adjusted EBITDA floor holds. The shares closed at $51.65 on 28 October 2026, the last close before the report, and the reaction to the numbers is not in the price yet.

The 2026 guidance for adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) is $185–225 million, narrowed on 29 July 2026 from $170–230 million. J Capital Research challenged that range on 1 October 2026, and the company has not answered with new disclosures. The shares have since moved from $46.48 on 2 October 2026 to $51.65, a recovery that rests on no new company data.

The narrative is maturing: the story is well known, the J Capital critique has been absorbed by the price, and the 29 October 2026 report is the next hard fact. The 14-day relative strength index (RSI) was 56.5 on 28 October 2026, against 28.7 on 2 October 2026.

Bullish and bearish views on Insperity, Inc

The bull case on Insperity, Inc (NSP), in brief: Profit recovery has reported support. The bear case: A critical report targets the guidance.

Bull case

• Profit recovery has reported support. Insperity's 29 July 2026 release showed second-quarter adjusted EBITDA of $36 million, up 13% year over year, and net income up 180% to $4 million.
• Volume guidance is steadier. The company set third-quarter average paid worksite employees at 305,500–307,500 on 29 July 2026. The second-quarter average was 305,764, above the floor of that range.
• Analyst targets sit above the price. MarketBeat reported an average target of $53.33 on 7 October 2026. Argus raised its target to $54 on 16 September 2026, and Roth Capital's target after the second quarter was $59. The close on 28 October 2026 was $51.65.
• The second quarter beat expectations. MarketBeat reported on 7 October 2026 earnings of $0.34 per share against $0.32 expected, and revenue of $1.69 billion against $1.67 billion expected.

Bear case

• A critical report targets the guidance. J Capital's 1 October 2026 report calls the roughly 56% midpoint profit increase subject to considerable uncertainty and describes a low-profit, low-growth business facing tough competition.
• HRScale accounting is questioned. J Capital says HRScale launched with very few beta clients while an accounting rule lets the company capitalize costs that were previously expensed. Insperity's 29 July 2026 disclosures showed Workday HRScale partnership costs of $8 million in the second quarter and $16 million year to date.
• Cash generation is cited as short of the dividend. J Capital says operating cash flow has not covered capital spending plus the dividend cumulatively since end 2023. The $0.60 quarterly dividend went ex on 2 September 2026.
• Gross profit still contracted. Second-quarter revenue rose 2% to $1.686 billion while gross profit fell 3% to $217 million. Management cited elevated healthcare cost inflation as a margin risk on the 29 July 2026 call.
• The third quarter permits weakness. Guidance allows adjusted EBITDA of $14–41 million and adjusted earnings per share of negative $0.09 to positive $0.41. Guided worksite employees are down 1.7–2.3% from the third quarter of 2025.
• Last year's third-quarter report hurt. StockStory reported the shares fell 25.7% after the third-quarter 2025 report, when full-year adjusted EPS guidance was cut to a $1.16 midpoint.
• Analyst opinion is split. MarketBeat on 7 October 2026 listed one buy, two hold and two sell ratings, a consensus of reduce. JPMorgan's underweight target was $33 after the second quarter.

Price setup

The 28 October 2026 close of $51.65 is 5.1% below the 52-week high of $54.44, measured on adjusted daily closes. The three-month price change is a gain of 3.3%. The early-October closes of $46.42 and $46.48, which followed J Capital's report, mark the low of the recent range.

The shares trade between those early-October closes and the 52-week high, a spread of roughly eight dollars that the report will likely resolve in one direction. Crowding evidence is limited to the earnings date itself, which falls on the next session after this close, and to a consensus rating of reduce, which means few analysts are positioned for upside. Adjusted closes carry the 2 September 2026 dividend, so they read below unadjusted quotes from before that date.

Catalysts, next 30 days

• Following days: Analyst target revisions after the report. Coverage is thin, so a single change moves the aggregate target.

Elapsed catalysts

• 29 October 2026: Third-quarter 2026 results before the NYSE open, with a call at 8:30 a.m. ET. The report tests the 305,500 worksite-employee floor, the $14–41 million adjusted EBITDA range and the $185 million full-year floor. (passed 8d ago)
• ~5 November 2026, est.: Third-quarter Form 10-Q. It would show whether operating cash flow covered capital spending plus the $2.40 annual dividend, the point J Capital raised. (passed 1d ago)

What would change the view

The operating case breaks if third-quarter average paid worksite employees come in below 305,500, if full-year adjusted EBITDA guidance falls below $185 million, or if gross profit contracts again by a wide margin against the third quarter of 2025. Any of those would confirm J Capital's argument that the guidance was too high.

The price condition is a daily close below $46, under the early-October closes of $46.42 and $46.48. A report that holds the $185 million floor, shows employee counts at or above 305,500 and a 10-Q with operating cash flow covering capital spending and the dividend would weaken the critical case. Even then, gross profit growth would still need to turn positive for the margin-repair story to be confirmed.

What it trades with

No current theme carries the name. Insperity's results depend on the number of employees at small and mid-sized US businesses and on health-claim costs it passes through to clients. Other professional employer organizations and payroll providers face the same hiring and medical-cost conditions, though the report on 29 October 2026 is specific to Insperity. The J Capital report on 1 October 2026 was company-specific and moved the shares to $46.42 by 6 October 2026 without a documented move in peers.